Pulmonary fibrosis

This study tested whether low doses of the hormone drug danazol can slow the shortening of telomeres—the protective caps on DNA—in people with telomere diseases. These conditions can cause bone marrow failure, lung scarring, and liver damage. Eighteen participants took danazol fo…

This study tested whether nintedanib, a drug used for other lung diseases, can slow down lung damage in people who had severe COVID-19. It included 103 adults who still had lung problems more than 30 days after their COVID diagnosis. The main goal was to see if the drug helped ma…

This study tested a single intravenous infusion of stem cells from donated umbilical cord tissue in one person with severe scleroderma that had caused lung scarring and high blood pressure in the lungs. The goal was to see if the treatment could improve lung function, exercise ab…

This study tested whether the antioxidant N-acetylcysteine (NAC) can slow lung decline in people with idiopathic pulmonary fibrosis (IPF) who have a specific gene variant (TOLLIP TT). Over 200 participants took NAC or a placebo for 24 months. The goal was to see if NAC delays wor…

This study looked at the long-term safety of a medicine called nintedanib in children and teenagers with a rare lung condition that causes scarring (fibrosing interstitial lung disease). All 54 participants took nintedanib capsules twice a day for at least 1.5 to 3 years. The goa…

This Phase 2 trial tested an experimental drug called BMS-986278 in 403 adults with pulmonary fibrosis, a condition that causes lung scarring and breathing difficulty. The study compared the drug to a placebo to see if it could improve lung function and was safe. Results will hel…

This study tested whether adding rituximab (a drug that calms certain immune cells) to standard mycophenolate mofetil treatment helps people with interstitial lung disease whose lungs are not responding to initial therapy. 122 adults with various ILD types received either rituxim…

This study tested an experimental oral drug called INS018_055 in 71 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. The main goal was to see if the drug is safe and tolerable over 12 weeks compared to a placebo. Resea…

This study tested whether rituximab, a drug used for certain cancers and autoimmune diseases, can reduce joint pain and swelling in people with systemic sclerosis (scleroderma). Twenty-two adults with active arthritis took rituximab or a placebo, plus standard care. Researchers c…

This small pilot study looked at whether the drug pirfenidone is safe and effective for people with a specific type of lung scarring (pulmonary fibrosis) linked to MPO antibodies or vasculitis. Seven adults took the drug for a year, and researchers measured changes in lung functi…

This study tested whether a combination of the chemotherapy drug cyclophosphamide and the steroid prednisone could help people with scleroderma-related lung disease. Forty adults whose lung function had worsened in the past year received either the drug combo or a placebo plus pr…

Pulmonary fibrosis is a chronic lung condition that causes breathlessness and often brings anxiety and depression, yet few psychological supports exist. This trial tests a 4-week online mindfulness program, called Compassionate Mindful Resilience, designed to improve emotional we…

This study followed 18 people in Spain with idiopathic pulmonary fibrosis (IPF) or other progressive lung scarring who were taking nintedanib (OFEV) and had developed diarrhea. The goal was to see if the diarrhea could be controlled after 12 weeks while staying on the full dose. …

This study tested a new automatic oxygen device in 29 people with fibrotic lung disease (scarred lungs). The device automatically adjusts oxygen flow during walking to keep oxygen levels steady. The goal was to see if it reduces breathlessness compared to the usual fixed oxygen d…

This early-stage trial is testing a new drug called HRS-9813 in 20 healthy volunteers to see how it interacts with two standard treatments for pulmonary fibrosis (lung scarring): pirfenidone and nintedanib. The goal is to measure drug levels in the blood and check for side effect…

This study follows 157 adults with pulmonary fibrosis who are taking nintedanib and enrolled in a patient support program in Spain. Researchers will measure how satisfied patients are with the program, their quality of life, and any depression symptoms over 12 months. The goal is…

This completed Phase 1 trial studied how deupirfenidone (LYT-100) and nintedanib interact in 24 healthy adults aged 18-65. Participants took both drugs over several weeks to measure drug levels and check for side effects. The goal was to understand potential drug-drug interaction…

This study tested a special MRI technique called magnetic resonance elastography (MRE) to see if it can detect scarring in transplanted kidneys. Researchers compared MRE results with traditional biopsy samples from 73 kidney transplant patients. The goal was to find a non-invasiv…

This study tested a new way for doctors to discuss CPR with older, seriously ill patients and their families. Instead of the usual conversation, doctors followed a step-by-step guide that focused on the patient's values and explained why CPR might not help. The goal was to see if…

This study followed 51 people with idiopathic pulmonary fibrosis (IPF) for 6 months to understand how their shortness of breath changes over time. Researchers measured both the physical sensation and the emotional impact of breathlessness, and looked at how these relate to lung f…

This study tested whether a special MRI technique can measure lung stiffness in people with scleroderma, a disease that often causes lung scarring. Researchers enrolled 24 adults and compared MRI results to standard lung function tests. The goal was to see if MRI could offer a sa…

This study tested three different oximeters (Masimo, Nellcor, Nonin) at various oxygen targets in 40 patients with and without COPD. The goal was to see how the choice of oximeter and target affects the amount of oxygen needed. Results could help guide safer oxygen therapy.

This early-stage study tested the safety and how the body handles an inhaled drug called CHF10073 in 155 healthy volunteers. The drug is being developed for pulmonary fibrosis, a serious lung-scarring condition. The trial looked at different single and multiple doses, and also ch…

This study looked at 250 people to understand why some smokers develop a rare lung condition called combined pulmonary fibrosis and emphysema (CPFE). Researchers compared telomere length and genetic mutations in patients with CPFE, those with only fibrosis or emphysema, and healt…

This study tested a new drug called 9MW3811 for the first time in humans. The main goal was to check if it is safe and how well it is tolerated in 32 healthy adults aged 18 to 55. Researchers gave a single dose and monitored for side effects, measuring how the drug moves through …

This study tested whether an AI tool called Lunit INSIGHT CXR helps healthcare professionals read chest X-rays more accurately and quickly. Thirty doctors and radiographers reviewed 500 past chest X-rays from two UK hospitals, once with and once without AI help. The goal was to s…

This study followed 38 adults who survived severe breathing failure from the 2009 H1N1 flu. Researchers compared those who needed a machine to oxygenate their blood (ECMO) with those who did not. They measured lung function, quality of life, and mental health at least 9 months af…

This completed study looked at 143 people with two types of lung scarring diseases (IPF and hypersensitivity pneumonitis). Researchers compared three different scoring systems (GAP, ILD-GAP, and CPI) to see which one best predicts how long patients might live. The goal was to fin…